Inbiomotion and SPA - Società Prodotti Antibiotici (SPA Farma) sign an exclusive agreement for MAF Test® in Italy

by Inbiomotion

This pioneering test aids oncologists in predicting recurrence and survival rates in breast cancer patients and potential eligibility for bisphosphonate treatment.

Read more

Inbiomotion and Source BioScience sign an exclusive agreement for MAF Test® in United Kingdom and Ireland

by Ysios Capital

Source BioScience, an industry-leading provider of genomic services and healthcare diagnostics, and Inbiomotion, a company commercializing its proprietary MAF Test® for identifying high risk early-st...

Read more

Inbiomotion and The Scientific Group sign an exclusive distribution agreement of MAF Test® for the Sub-Saharan Africa

by Ysios Capital

This pioneering test aids oncologists in predicting recurrence and survival rates in breast cancer patients and potential treatment eligibility to bisphosphonates

Read more

Palex and Inbiomotion introduce pioneering test to aid oncologists in predicting recurrence and survival rates in breast cancer patients

by Ysios Capital

The MAF-TEST® predicts the prognosis of breast cancer patients and helps oncologists to identify those patients who may be able to prevent recurrence and benefit from adjuvant treatment with bisphosp...

Read more

Alta Life Sciences leads an oversubscribed investment round into Inbiomotion to launch its diagnostic product in breast cancer

by Inbiomotion

​Inbiomotion SL has announced that Alta Life Sciences has led its significantly oversubscribed investment round. Alta Life Sciences Spain I FCR is a leading venture capital fund managed by Altamar P...

Read more

La Caixa leads an investment round in Inbiomotion with the participation of Ysios Capital

by Professional Newco

The fund is driven by ”la Caixa” and the Centro para el Desarrollo Tecnológico Industrial (Centre for Industrial Technological Development, CDTI) under the framework of the Innvierte Programme an...

Read more

Inbiomotion and Peptomyc receive funding through European Horizon 2020 program

by Biocat

In the final round of selection, the European Horizon 2020 has chosen two Catalan start-ups from the health sector: Inbiomotion and Peptomyc, which will receive €50,000 to fund their innovative proj...

Read more

IRB Barcelona identifies the gene responsible for metastasis of breast cancer to the bone

by IRB Barcelona - Instituto de Investigación Biomédica

A study published in the Journal of National Cancer Institute (JNCI) by ICREA researcher Roger Gomis may be key to the early detection of patients at risk of developing metastasis to the bone. This ne...

Read more
Subscribe to Directory
Write an Article

Recent News

Exposure to Heat and Cold During Pregnan...

The research team observed changes in head circumf...

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

El diagnóstico genético neonatal mejor...

Un estudio con datos de los últimos 35 años, ind...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

Seven key genetic profiles associated wi...

by Fundació Clínic per a la Recerca Biomèdica

A study published in Nature Communications has identified different ri...

Photos Stream